FDA to review anti-arrhythmic claims for CV Therapeutics’s Ranexa
This follows the FDA’s acceptance of a supplemental new drug application (sNDA) seeking expansion to the approved product labeling for Ranexa to include a first-line angina indication and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.